CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 301-306

  Trojan, Andreas ^a,b   Vergopoulos, Athanasios ^c   Breitenstein, Urs ^a,b   Tausch, Christoph ^b   Seifert, Burkhardt ^d   Joechle, Wolfgang ^e  

^a KLINIK IM PARK   (Switzerland)

^b Breast Center Zurich   (Switzerland)

^c Laboratory Enders and Partner   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e MLO Medizinisches Labor AG   (Switzerland)

Author keywords

CYP2D6 phenotype; Dextromethorphan metabolism; Disease free survival; Early breast cancer; Tamoxifen

Indexed keywords

ANTIESTROGEN; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; TREATMENT OUTCOME; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; PHENOTYPE; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 84874118766     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2003-y     Document Type: Article

References (42)

1. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10(8):825-833
2. Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28(8):1287-1293
3. Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Clin Oncol 23(36):9312-9318
4. Punglia RS, Burstein HJ, Winer EP, Weeks JC (2008) Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 100(9):642-648
5. Higgins MJ, Stearns V (2011) Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 62:281-293
6. Goetz MP, Schaid DJ, Wickerham DL et al (2011) Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res 17(21):6944-6951
7. Gjerde J, Hauglid M, Breilid H et al (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19(1):56-61
8. Borges S, Desta Z, Jin Y et al (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50(4):450-458
9. Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30-39
10. Schroth W, Goetz M, Hamann U et al (2009) Association between CYP2D6 Polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436
11. Ratliff B, Dietze EC, Bean GR et al (2004) Re: active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 96:883-885
12. Trojan A, Vergopoulos A, Breitenstein U et al (2012) The discriminatory value of CYP2D6 genotyping in predicting the Dextromethorphan/Dextrorphan phenotype in women with breast cancer. Breast Care 7:25-31
13. Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international Group 1-98 trial. J Natl Cancer Inst 104(6):441-451
14. Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(6):452-460
15. Nakamura Y, Ratain MJ, Cox NJ et al (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(16):1264
16. Stanton V Jr (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(16):1265-1266
17. Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the BIG 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(16):1263-1264
18. Viale G, Regan MM, Maiorano E et al (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 26(9):1404-1410
19. Irvin WJ Jr, Walko CM, Weck KE et al (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29(24):3232-3239
20. Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89(5):718-725
21. Ducharme J, Abdullah S, Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678(1):113-128
22. Streetman DS, Bleakley JF, Kim JS et al (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther 68(4):375-383
23. de Graan AJ, Teunissen SF, de Vos FY et al (2011) Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 29(24):3240-3246
24. Siegelmann-Danieli N, Kurnik D, Lomnicky Y et al (2011) Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125(2):505-510
25. Yu A, Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities. Drug Metab Dispos 29:1514-1520
26. Brauch H, Muerdter TE, Eichelbaum M, Schwab M (2009) Pharmacogenetics of Tamoxifen therapy. Clin Chem 55(10):1770-1782
27. Abdel-Rahman SM, Leeder JS, Wilson JT et al (2002) Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 42(1):24-29
28. Blake MJ, Gaedigk A, Pearce RE et al (2007) Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 81(4):510-516
29. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784
30. Wegman P, Elingarami S, Carstensen J et al (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9(1):R7
31. Nowell SA, Ahn J, Rae JM et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91(3):249-258
32. Barginear MF, Jaremko M, Peter I et al (2011) Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 90(4):605-611
33. Shi L, Dong B, Li Z, Lu Y et al (2009) Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27(21):3423-3429
34. Pagani O, Gelber S, Simoncini E et al (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 116(3):491-500
35. Iwamoto T, Booser D, Valero V et al (2012) Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30:729-734
36. Rae JM, Sikora MJ, Henry NL et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9(4):258-264
37. Goetz MP, Knox SK, Suman VJ et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101(1):113-121
38. Thompson AM, Johnson A, Quinlan P et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279-287
39. Gor PP, Su HI, Gray RJ et al (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 12(3):R26
40. Martínez Guisado A, Sánchez Muñoz A, de la Cabeza Lomas Garrido M et al (2011) Initialization of adjuvant hormonal treatment for breast cancer. Adv Ther. 28(Suppl 6):66-84
41. Loos WJ, de Graan AJ, de Bruijn P et al (2011) Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal 54(2):387-394
42. Barrière J, Formento JL, Milano G et al (2010) CYP2D6 polymorphisms and therapeutic perspectives in the management of hormonodependent breast cancer patients. Bull Cancer 97(3):311-320